ESALF - Biogen investors expect company to win approval for Alzheimer's drug: RBC survey

A majority of Biogen ([[BIIB]] -1.8%) investors predict the company to win the FDA approval for experimental Alzheimer’s disease therapy aducanumab albeit with restrictions, according to a survey conducted by RBC Capital Markets.With restrictive monitoring requirements, the FDA approval will narrow its use to a select group of patients, most of the respondents in the survey have indicated.Rejection of approval could lead to a 30% drop in Biogen shares, 40% of the respondents have said in the study that involved 47 mainly specialist investors.Full approval and conditional approval will add 50% and 20%, respectively, wrote analyst Brian Abrahams citing the survey.In January, the FDA extended the review period of the Biologics License Application ((BLA)) filed by Biogen and Eisai Co. (ESALF) for aducanumab by three months making June 07 the new PDUFA date.

For further details see:

Biogen investors expect company to win approval for Alzheimer’s drug: RBC survey